Should I buy or sell DiaMedica Therapeutics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DiaMedica Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DMAC shares. View DMAC analyst ratings or view top-rated stocks .

What is DiaMedica Therapeutics' stock price target for 2024?

2 Wall Street analysts have issued twelve-month price objectives for DiaMedica Therapeutics' stock. Their DMAC share price targets range from $6.00 to $8.00. On average, they predict the company's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 195.4% from the stock's current price. View analysts price targets for DMAC or view top-rated stocks among Wall Street analysts .

How have DMAC shares performed in 2024?

DiaMedica Therapeutics' stock was trading at $2.84 on January 1st, 2024. Since then, DMAC stock has decreased by 16.5% and is now trading at $2.37. View the best growth stocks for 2024 here .

When is DiaMedica Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our DMAC earnings forecast .

How were DiaMedica Therapeutics' earnings last quarter?

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) announced its quarterly earnings data on Wednesday, March, 20th. The company reported ($0.14) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.14).

What other stocks do shareholders of DiaMedica Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DiaMedica Therapeutics investors own include VBI Vaccines (VBIV) , Inovio Pharmaceuticals (INO) , Dynavax Technologies (DVAX) , Pfizer (PFE) , Vaxart (VXRT) , Aldeyra Therapeutics (ALDX) , Capricor Therapeutics (CAPR) , Oncolytics Biotech (ONCY) , Sesen Bio (SESN) and Sorrento Therapeutics (SRNE) .

When did DiaMedica Therapeutics IPO?

DiaMedica Therapeutics (DMAC) raised $18 million in an initial public offering (IPO) on Friday, December 7th 2018. The company issued 4,000,000 shares at $4.00-$5.00 per share. Craig-Hallum Capital Group acted as the underwriter for the IPO.

How do I buy shares of DiaMedica Therapeutics?

Shares of DMAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:DMAC

DiaMedica Therapeutics (DMAC) Stock Price, News & Analysis

→ Can't believe it's happening again (From Manward Press) (Ad)

Free DMAC Stock Alerts

$2.37

-0.02 (-0.84%)

(As of 05:12 PM ET)

Compare

Today's Range: $2.29
▼
$2.41
50-Day Range: $2.39
▼
$3.23
52-Week Range: $1.50
▼
$4.75

Volume: 16,028 shs
Average Volume: 43,188 shs
Market Capitalization: $89.97 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.00

Get DiaMedica Therapeutics alerts:

DiaMedica Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 195.4% Upside
$7.00 Price Target
Short Interest: Healthy
0.53% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.13 out of 5 stars

Medical Sector

802nd out of 930 stocks

Pharmaceutical Preparations Industry

362nd out of 420 stocks

3.5

Analyst's Opinion

Consensus Rating
DiaMedica Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
DiaMedica Therapeutics has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.53% of the outstanding shares of DiaMedica Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
DiaMedica Therapeutics has a short interest ratio ("days to cover") of 4.8.
Change versus previous month
Short interest in DiaMedica Therapeutics has recently decreased by 4.89%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
DiaMedica Therapeutics does not currently pay a dividend.
Dividend Growth
DiaMedica Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for DMAC.

1.9

News and Social Media Coverage

News Sentiment
DiaMedica Therapeutics has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.
MarketBeat Follows
6 people have added DiaMedica Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, DiaMedica Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 7.20% of the stock of DiaMedica Therapeutics is held by insiders.
Percentage Held by Institutions
Only 10.12% of the stock of DiaMedica Therapeutics is held by institutions.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of DiaMedica Therapeutics is -3.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of DiaMedica Therapeutics is -3.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
DiaMedica Therapeutics has a P/B Ratio of 1.76. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

Trump’s “Tax Free” Retirement Strategy

Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.

Protect your retirement savings from the inevitable devaluation of the dollar…

About DiaMedica Therapeutics Stock (NASDAQ:DMAC)

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. The company develops treatments for neurological disorders and cardio-renal disease. Its lead candidate is DM199, a pharmaceutically active recombinant form of the kallikrein-1 protein for the treatment of acute ischemic stroke and other vascular diseases. It is also developing DM300 that is in preclinical stage of development for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

DMAC Stock Price History

30 days | 90 days | 365 days | Advanced Chart

DMAC Stock News Headlines

March 25, 2024 | finance.yahoo.com

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2023 Earnings Call Transcript

March 23, 2024 | investorplace.com

Wall Street's Favorite Penny Stocks? 7 Names That Could Make You Filthy Rich

April 16, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

March 22, 2024 | seekingalpha.com

DiaMedica Therapeutics Inc. (DMAC) Q4 2023 Earnings Call Transcript

March 19, 2024 | investorplace.com

DMAC Stock Earnings: DiaMedica Therapeutics Meets EPS for Q4 2023

March 19, 2024 | benzinga.com

Recap: DiaMedica Therapeutics Q4 Earnings

March 19, 2024 | businesswire.com

DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results

March 6, 2024 | ca.finance.yahoo.com

Tryp Therapeutics Inc. (TRYP.CN)

April 16, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

February 9, 2024 | benzinga.com

DiaMedica Therapeutics Stock (NASDAQ:DMAC) Dividends: History, Yield and Dates

January 29, 2024 | finance.yahoo.com

DiaMedica Therapeutics Announces Poster Presentation at International Stroke Conference

January 7, 2024 | finance.yahoo.com

DiaMedica Therapeutics Inc.'s (NASDAQ:DMAC) largest shareholders are individual investors with 52% ownership, insiders own 37%

December 11, 2023 | finance.yahoo.com

Here's Why We're Not Too Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Situation

November 15, 2023 | finance.yahoo.com

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q3 2023 Earnings Call Transcript

November 14, 2023 | markets.businessinsider.com

Analysts’ Top Healthcare Picks: Diamedica Therapeutics (DMAC), Abivax SA Sponsored ADR (ABVX)

November 14, 2023 | finance.yahoo.com

Q3 2023 DiaMedica Therapeutics Inc Earnings Call

November 14, 2023 | gurufocus.com

DiaMedica Therapeutics Inc. (DMAC) Reports Third Quarter 2023 Financial Results

November 14, 2023 | finance.yahoo.com

DiaMedica Therapeutics Insiders Placed Bullish Bets Worth US$20.2m

November 13, 2023 | msn.com

DiaMedica Therapeutics GAAP EPS of -$0.12 beats by $0.01

November 13, 2023 | finance.yahoo.com

DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial Results

November 10, 2023 | benzinga.com

Earnings Outlook For DiaMedica Therapeutics

November 9, 2023 | finance.yahoo.com

DiaMedica Therapeutics to Attend the 14th Annual Craig-Hallum Alpha Select Conference November 16, 2023

November 6, 2023 | finance.yahoo.com

DiaMedica Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update November 14, 2023

September 12, 2023 | finance.yahoo.com

DiaMedica Therapeutics Announces the Appointment of Ambarish Shah, Ph.D. as Chief Technology Officer

September 6, 2023 | finance.yahoo.com

DiaMedica Therapeutics to Participate at Lake Street’s 7th Annual Best Ideas Growth Conference

August 31, 2023 | finance.yahoo.com

Is DiaMedica Therapeutics (DMAC) Stock Outpacing Its Medical Peers This Year?

August 15, 2023 | finance.yahoo.com

Q2 2023 DiaMedica Therapeutics Inc Earnings Call

See More Headlines

Receive DMAC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DiaMedica Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/20/2024
Today: 4/16/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:DMAC
CUSIP: N/A
CIK: 1401040
Web: www.diamedica.com
Phone: (763) 496-5454
Fax: N/A
Employees: 18
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $7.00
High Stock Price Target: $8.00
Low Stock Price Target: $6.00
Potential Upside/Downside: +195.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.62)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-19,380,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -40.07%
Return on Assets: -37.90%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 19.27
Quick Ratio: 19.27

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.35 per share
Price / Book: 1.76

Miscellaneous

Outstanding Shares: 37,960,000
Free Float: 35,225,000
Market Cap: $89.97 million
Optionable: Optionable
Beta: 1.69

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Mr. Dietrich John Pauls MBA (Age 53)
President, CEO & Director
Comp: $736.79k
Mr. Scott Kellen CPA (Age 59)
CFO & Company Secretary
Comp: $447.02k
Dr. Kirsten L. Gruis M.D. (Age 51)
M.S., Independent Consultant
Comp: $519.82k
Dr. Ambarish Shah Ph.D.
Chief Technology Officer
Mr. Dominic R. Cundari (Age 73)
Chief Commercial Officer
Ms. Julie VanOrsdel Daves CCRP (Age 50)
Senior Vice President of Clinical Development Operations
Mr. David J. Wambeke (Age 40)
Chief Business Officer
Dr. Lorianne K. Masuoka M.D. (Age 63)
Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

DMAC Stock Analysis - Frequently Asked Questions

Should I buy or sell DiaMedica Therapeutics stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DiaMedica Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DMAC shares.
View DMAC analyst ratings or view top-rated stocks.
What is DiaMedica Therapeutics' stock price target for 2024?: 2 Wall Street analysts have issued twelve-month price objectives for DiaMedica Therapeutics' stock. Their DMAC share price targets range from $6.00 to $8.00. On average, they predict the company's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 195.4% from the stock's current price.
View analysts price targets for DMAC or view top-rated stocks among Wall Street analysts.
How have DMAC shares performed in 2024?: DiaMedica Therapeutics' stock was trading at $2.84 on January 1st, 2024. Since then, DMAC stock has decreased by 16.5% and is now trading at $2.37.
View the best growth stocks for 2024 here.
When is DiaMedica Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our DMAC earnings forecast.

How were DiaMedica Therapeutics' earnings last quarter?: DiaMedica Therapeutics Inc. (NASDAQ:DMAC) announced its quarterly earnings data on Wednesday, March, 20th. The company reported ($0.14) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.14).
What other stocks do shareholders of DiaMedica Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other DiaMedica Therapeutics investors own include VBI Vaccines (VBIV), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Pfizer (PFE), Vaxart (VXRT), Aldeyra Therapeutics (ALDX), Capricor Therapeutics (CAPR), Oncolytics Biotech (ONCY), Sesen Bio (SESN) and Sorrento Therapeutics (SRNE).
When did DiaMedica Therapeutics IPO?: DiaMedica Therapeutics (DMAC) raised $18 million in an initial public offering (IPO) on Friday, December 7th 2018. The company issued 4,000,000 shares at $4.00-$5.00 per share. Craig-Hallum Capital Group acted as the underwriter for the IPO.
How do I buy shares of DiaMedica Therapeutics?: Shares of DMAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:DMAC) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial